Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages


This content is available also in other languages

April 22, 2009 | Corporate News | English

Annual General Meeting 2009: Tecan shareholders approved all motions proposed by the Board of Directors

  • Profit distribution through dividend payment of CHF 0.90 per registered share
  • Heinrich Fischer, Jürg Meier, Peter Ryser and Gérard Vaillant re-elected as members of the Board of Directors
  • Rolf Classon, Dominique F. Baly and Lukas Braunschweiler newly elected to
    the Board of Directors
  • Rolf Classon elected as Chairman immediately after the Annual General
  • Capital reduction through cancellation of registered shares

Männedorf, Switzerland, April 22, 2009 – The Annual General Meeting of Tecan Group AG
(SIX Swiss Exchange: TECN) has today approved all motions proposed by the Board of Directors. The shareholders approved the Annual Report, the financial statements and the consolidated financial statements and granted discharge to the Board of Directors and the Executive Committee. The shareholders approved an unchanged profit distribution of CHF 0.90 per registered share. The payout will take place on April 24, 2009.

Heinrich Fischer, Dr. Jürg Meier, Prof. Dr. Peter Ryser and Gérard Vaillant were re-elected as members of the Board of Directors of Tecan for a term of one year. The shareholders elected Rolf Classon, Dominique F. Baly and Dr. Lukas Braunschweiler as new members. Immediately after the Annual General Meeting, in its constitutive meeting, the Board of Directors elected Rolf Classon as the new Chairman. “I relish the task of doing all I can to help drive Tecan’s business forward. Tecan has a convincing strategy and is well positioned for further growth,” commented Rolf Classon.

Heinrich Fischer, Vice Chairman of the Board of Directors, bid farewell to Chairman Mike Baronian and members of the Board of Directors Cleto De Pedrini and Prof. Dr. Armin Seiler, who are also leaving, thanking them warmly for their many years of dedicated commitment and valuable contributions to the development of Tecan.

The shareholders approved the reduction in share capital through the cancellation of 696,788 registered shares (5.8% of the share capital). Tecan had acquired these shares as part of a share buyback program. The buyback program was launched in May 2008 as a means of reducing capital, via a second trading line on the SIX Swiss Exchange.
Due to the changed environment in the capital and credit markets, Tecan decided to cancel the program prematurely, effective March 4, 2009, and to instead build up additional cash resources to fund further growth. The shareholders also approved the change in the Articles of Incorporation which the capital reduction entailed.

KPMG AG, Zurich, was confirmed as statutory auditor for 2009.

Next date for the diary

The 2009 Interim Report will be published on August 13, 2009.


About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions for the biopharma, forensic and diagnostic industries. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. With its subsidiary REMP (www.remp.com), Tecan is the market leader in automated laboratory storage and logistics systems. Its clients include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).



For further information please contact:

Tecan Group
Dr. Rudolf Eugster
Chief Financial Officer


Martin Brändle
Head of Corporate Communications &
Investor Relations

Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89